Literature DB >> 11029133

Microbiologic contamination study of nebulizers after aerosol therapy in patients with cystic fibrosis.

S Vassal1, R Taamma, N Marty, A Sardet, P d'athis, F Brémont, M L Dalphin, P Plésiat, G Rault, J Thubert, S Dominique, J F Lemeland, J Derelle, M F Blech, M Roussey, M Perrin, A Sautegeau.   

Abstract

BACKGROUND: To evaluate the contamination of delivery systems after an aerosol therapy session in patients with cystic fibrosis who have chronic Pseudomonas aeruginosa infection.
METHODS: Fifty-three patients with cystic fibrosis were enrolled in the study from March 1996 to June 1997. All patients were age 7 years or older and had P aeruginosa infection. They also had been treated with recombinant deoxyribonuclease and were capable of producing sputum for culture.
RESULTS: Nine devices were excluded for the study. A total of 44 nebulizers were included: 37 from patients with P aeruginosa colonization with a count of 10(6) colony-forming units/mL or more and 7 with a count of between 10(5) colony-forming units/mL and 10(6) colony-forming units/mL.
CONCLUSION: This study demonstrates that in the absence of cleaning, nebulizers of patients with cystic fibrosis who are infected with P aeruginosa are likely to be contaminated by a pathogenic flora.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11029133     DOI: 10.1067/mic.2000.110214

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN: 0196-6553            Impact factor:   2.918


  8 in total

Review 1.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

Review 2.  Nebuliser hygiene in cystic fibrosis: evidence-based recommendations.

Authors:  Jane Bell; Lauren Alexander; Jane Carson; Amanda Crossan; John McCaughan; Hazel Mills; Damian O'Neill; John E Moore; B Cherie Millar
Journal:  Breathe (Sheff)       Date:  2020-06

Review 3.  Tobramycin inhalation powder for the treatment of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis: a review based on clinical evidence.

Authors:  Kamal Hamed; Laurie Debonnett
Journal:  Ther Adv Respir Dis       Date:  2017-02-17       Impact factor: 4.031

4.  Microbial contamination of home nebulizers in children with cystic fibrosis and clinical implication on the number of pulmonary exacerbations.

Authors:  Seyed Ahmad Tabatabaii; Ghamartaj Khanbabaee; Saeed Sadr; Nazanin Farahbakhsh; Maryam Kazemi Aghdam; Saran Lotfollahzadeh; Amirhossein Hosseini; Naghi Dara; Mohammad Nanbakhsh; Fatemeh Abdollah Gorji
Journal:  BMC Pulm Med       Date:  2020-02-06       Impact factor: 3.317

5.  Persistent Pseudomonas aeruginosa infection associated with non-invasive ventilation in a child with spinal muscular atrophy type 1.

Authors:  Archana Chacko; Peter D Sly; Tim Kidd; Leanne Gauld
Journal:  J Clin Sleep Med       Date:  2021-03-01       Impact factor: 4.062

6.  Effect that an educational program for cystic fibrosis patients and caregivers has on the contamination of home nebulizers.

Authors:  Adriana Della Zuana; Doroti de Oliveira Garcia; Regina Célia Turola Passos Juliani; Luiz Vicente Ribeiro Ferreira da Silva Filho
Journal:  J Bras Pneumol       Date:  2014 Mar-Apr       Impact factor: 2.624

7.  Cleaning and infection control of airway clearance devices used by CF patients.

Authors:  Eynav Manor; Michal Gur; Yuval Geffen; Lea Bentur
Journal:  Chron Respir Dis       Date:  2017-05-17       Impact factor: 2.444

8.  Bacterial Surface Detachment during Nebulization with Contaminated Reusable Home Nebulizers.

Authors:  Jamie C Harris; Melanie S Collins; Pamela H Huang; Craig M Schramm; Thomas Nero; Jing Yan; Thomas S Murray
Journal:  Microbiol Spectr       Date:  2022-02-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.